Prescription Drugs

Most new medicines are developed by unprofitable startups that can succeed under a wide range of pricing systems.

Congress and federal regulators have obstructed biosimilar competition, increasing patient costs by over $30 billion.

Changes to the island’s corporate tax code can return drugmakers from China, India, and Ireland.

The U.S. could deploy reference pricing to increase competition and lower costs.

Market-based policies from countries like Denmark and Singapore can make medicines more affordable in the U.S.

Sen. Elizabeth Warren’s new proposal fails to think through why there are generic drug shortages in the first place.

Pharmacy benefit managers and wholesalers have an obscure, but important, role in reducing the price of prescription medicines.

FDA acts on a key FREOPP recommendation for lowering the price of unaffordable prescription drugs.